{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:33:22Z","timestamp":1787790802380,"version":"build-2784847793"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Henry Schueler Foundation"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI181764-01"],"award-info":[{"award-number":["R01 AI181764-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI177098-02"],"award-info":[{"award-number":["R01AI177098-02"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI143409-05"],"award-info":[{"award-number":["R01-AI143409-05"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI169358-03"],"award-info":[{"award-number":["U01AI169358-03"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5P30-AI064518"],"award-info":[{"award-number":["5P30-AI064518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current Mycosis Study Group Education and Research Consortium (MSGERC) and European Confederation of Medical Mycology (ECMM) response criteria for clinical trials often fail to comprehensively assess outcomes of the total patient experience, prompting the need for innovative methodologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing a modified Delphi process, members of MSGERC and ECMM were sent a series of surveys utilizing an online platform. Except for the first survey, participants\u2019 responses remained anonymous to the steering committee. The first survey was elaborated based on expert opinion, with each subsequent round building upon the responses from previous rounds. Agreement was predefined by consensus of the steering committee as majority support, set at &amp;gt;70% agreement, for each survey component.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For invasive candidiasis, a composite of treatment failure and infectious complications were included to elaborate a DOOR scale, with endpoints measured at 2 weeks after initiation of therapy. For invasive aspergillosis, a composite of treatment failure, presence of disease-attributable complications, and treatment-related adverse events were included to elaborate a DOOR scale, with endpoints measured at 6 weeks after initiation of therapy. For cryptococcosis, a composite of treatment failure and adverse events were included to elaborate a DOOR scale, with endpoints measured at 4 weeks after initiation of therapy. For mucormycosis, treatment failure and adverse events were included to elaborate a DOOR scale, with endpoints measured at 6 and 12 weeks after initiation of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consensus endpoints were developed for invasive candidiasis, invasive aspergillosis, cryptococcosis, and mucormycosis for use in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag012","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T12:31:49Z","timestamp":1768653109000},"source":"Crossref","is-referenced-by-count":1,"title":["Development Framework of Desirability of Outcome Ranking Endpoints for Use in Clinical Trials of Invasive Fungal Diseases"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0688-1033","authenticated-orcid":false,"given":"Jose","family":"Portugal Gonzales","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-4396","authenticated-orcid":false,"given":"Neil M","family":"Ampel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Arizona , Tucson, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Boulware","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-5693","authenticated-orcid":false,"given":"Fariba M","family":"Donovan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Arizona , Tucson, Arizona ,","place":["USA"]},{"name":"Department of Internal Medicine, Valley Fever Center for Excellence , Tucson, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-6580","authenticated-orcid":false,"given":"Thuy","family":"Le","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd P","family":"McCarty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-0512","authenticated-orcid":false,"given":"Marisa H","family":"Miceli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"McGwin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-9931","authenticated-orcid":false,"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-5395","authenticated-orcid":false,"given":"Alessandro C","family":"Pasqualotto","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Santa Casa de Porto Alegre , Porto Alegre ,","place":["Brazil"]},{"name":"Department of Clinical Medicine, Federal University of Health Sciences of Porto Alegre , Porto Alegre ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of California\u2014Davis , California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center for Innovative Therapeutics and Diagnostics , Richmond, Virginia ,","place":["USA"]},{"name":"Departments of Medicine and Microbiology & Immunology, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-7589","authenticated-orcid":false,"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026013002065583500_ofag012-B1","doi-asserted-by":"crossref","first-page":"e0014223","DOI":"10.1128\/cmr.00142-23","article-title":"Advancements and challenges in antifungal therapeutic development","volume":"37","author":"Puumala","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2026013002065583500_ofag012-B2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/320876","article-title":"Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses","volume":"33","author":"Rex","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026013002065583500_ofag012-B3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026013002065583500_ofag012-B4","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkae158","article-title":"Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases\u2014a debate","volume":"79","author":"Maertens","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026013002065583500_ofag012-B5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026013002065583500_ofag012-B6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026013002065583500_ofag012-B7","doi-asserted-by":"crossref","first-page":"ofac140","DOI":"10.1093\/ofid\/ofac140","article-title":"A desirability of outcome ranking analysis of a randomized clinical trial comparing seven versus fourteen days of antibiotics for uncomplicated gram-negative bloodstream infection","volume":"9","author":"Howard-Anderson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026013002065583500_ofag012-B8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","article-title":"Unlocking the DOOR\u2014how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials","volume":"29","author":"Ong","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026013002065583500_ofag012-B9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"2026013002065583500_ofag012-B10","first-page":"10","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"2026013002065583500_ofag012-B11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2026013002065583500_ofag012-B12"},{"key":"2026013002065583500_ofag012-B13","author":"Center for Drug Evaluation and Research"},{"key":"2026013002065583500_ofag012-B14","doi-asserted-by":"crossref","first-page":"e078000","DOI":"10.1136\/bmj-2023-078000","article-title":"Exploring different objectives in non-inferiority trials","volume":"385","author":"Tweed","year":"2024","journal-title":"BMJ"},{"key":"2026013002065583500_ofag012-B15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"Latg\u00e9","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"2026013002065583500_ofag012-B16","doi-asserted-by":"crossref","first-page":"ofae257","DOI":"10.1093\/ofid\/ofae257","article-title":"Meeting the therapeutic challenges of emergent and rare invasive fungal diseases through novel clinical trial designs","volume":"11","author":"Walsh","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026013002065583500_ofag012-B17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.cmi.2021.11.003","article-title":"Methodological and reporting quality of non-inferiority randomized controlled trials comparing antifungal therapies: a systematic review","volume":"28","author":"Komorowski","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026013002065583500_ofag012-B18","doi-asserted-by":"crossref","first-page":"e13888","DOI":"10.1111\/tid.13888","article-title":"Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation","volume":"24","author":"Doernberg","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2026013002065583500_ofag012-B19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s15010-011-0108-6","article-title":"The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis","volume":"39","author":"Schwartz","year":"2011","journal-title":"Infection"},{"key":"2026013002065583500_ofag012-B20","doi-asserted-by":"crossref","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026013002065583500_ofag012-B21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10096-018-3441-1","article-title":"Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia","volume":"38","author":"Giacobbe","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026013002065583500_ofag012-B22","doi-asserted-by":"crossref","first-page":"e0004325","DOI":"10.1128\/jcm.00043-25","article-title":"Evaluating antimicrobial stewardship strategies in candidemia: a novel desirability of outcome ranking (DOOR) analysis comparing blood culture versus T2Candida diagnostic approaches","volume":"63","author":"Caniff","year":"2025","journal-title":"J Clin Microbiol"},{"key":"2026013002065583500_ofag012-B23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/cid\/ciad576","article-title":"Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"78","author":"Howard-Anderson","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026013002065583500_ofag012-B24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/cid\/civ1002","article-title":"DOOR\/RADAR: a gateway into the unknown?","volume":"62","author":"Phillips","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag012\/66504589\/ofag012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofag012\/66504589\/ofag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofag012\/66504589\/ofag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:07:04Z","timestamp":1769756824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag012\/8434499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag012","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"ofag012"}}